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Background: Liver fat and visceral adiposity are involved in the development of the metabolic
syndrome (MetS). Ectopic fat accumulation within and around the heart has been related to
increased risk of heart disease. The aimof this studywas to explore components of cardiac steatosis
and their relationship to intra-abdominal ectopic fat deposits and cardiometabolic risk factors in
nondiabetic obese men.
Methods: Myocardial and hepatic triglyceride (TG) contents were measured with 1.5 T magnetic
resonance spectroscopy, and visceral adipose (VAT), abdominal subcutaneous tissue (SAT), epicar-
dial and pericardial fat by magnetic resonance imaging in 37 men with the MetS and in 40 men
without the MetS.
Results:Myocardial and hepatic TG contents, VAT, SAT, epicardial fat volumes, and pericardial fat
volumes were higher in men with the MetS compared with subjects without the MetS (P  .001).
All components of cardiac steatosis correlated with SAT, VAT, and hepatic TG content and the
correlations seemed to be strongest with VAT. Myocardial TG content, epicardial fat, pericardial
fat, VAT, and hepatic TG content correlated with waist circumference, body mass index, high-
density lipoprotein cholesterol TGs, very low-density lipoprotein-1 TGs, and the insulin-resistance
homeostasis model assessment index. VAT was a predictor of TGs, high-density lipoprotein cho-
lesterol, and measures of glucose metabolism, whereas age and SAT were determinants of blood
pressure parameters.
Conclusions:We suggest that visceral obesity is the best predictor of epicardial and pericardial fat
in abdominally obese subjects. Myocardial TG content may present a separate entity that is influ-
enced by factors beyond visceral adiposity. (J Clin Endocrinol Metab 98: 1189–1197, 2013)
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Obesity is aworldwide epidemic associatedwith excesscardiovascular deaths (1–3). Recent data highlight
that central obesity has deleterious consequences on car-
diovascular health (4). The inability of adipose tissue to
expand and to store fat results in lipid overflow to other
organs in the setting of excess caloric intake and physical
inactivity. Metabolically deleterious and life-threatening
forms of obesity associate with an excess accumulation of
fat in the visceral adipose tissue (VAT) andwith ectopic fat
deposition in organs that usually contain minor amounts
of fat, suchas skeletalmuscle, liver, pancreas, andheart (5,
6).This aberrant fat accumulation strongly correlateswith
unfavorable metabolic profile comprising insulin resis-
tance, dyslipidemia, and the development of a chronic in-
flammatory state (7). Thus, the site of fat accumulation
seems to have important metabolic implications with re-
spect to rates of cardiovascular morbidity and mortality
andhas raised the concept of healthy vs unhealthy obesity.
Protonmagnetic resonance spectroscopy (1HMRS)has
become the gold standard to quantitate liver fat content.
Recently, 1H MRS has been tested as a valid and repro-
ducible technique for noninvasive measurement of myo-
cardial triglyceride (TG) content in humans (8, 9). This
technique has revealed also that myocardial TG is a com-
ponent of ectopic fat depots and a cardiometabolic risk
marker. Thus, myocardial TG content is reported to be
higher in obesity (10), in subjects with impaired glucose
tolerance (11), and inpersonswith type2diabetesmellitus
(12, 13). Elevation of myocardial fat has detrimental met-
abolic consequences, including impaired lipid oxidation,
oxidative stress, and mitochondrial defects (14–16). This
cardiac lipotoxicity is considered to reflect the deleterious
effects of the accumulation of lipid and other toxic prod-
ucts of free fatty acid metabolism within myocardial tis-
sue. Data accumulating from animal studies have pro-
vided consistent evidence that cardiac lipotoxicity impairs
left ventricular (LV) function and promotes cardiac fibro-
sis and apoptosis (14, 15, 17).
Hepatic lipid overloading is the hallmark of nonalcoholic
liver disease, which is highly prevalent in obesity and asso-
ciates strongly with visceral adiposity (18). The coexistence
of these ectopic fat depots associates with multiple car-
diometabolic risk factors, including insulin resistance,
hypertension, hyperglycemia, hypertriglyceridemia, re-
duced high-density lipoprotein cholesterol (HDL-C),
and intra-abdominal obesity. This constellation of met-
abolic abnormalities has been nominated as themetabolic
syndrome (MetS) (19), which is widely accepted as a prac-
tical tool to identify centrally obese persons at high risk. It
should be noted, however, that the MetS as such does not
exceed the risk associatedwith the individual components
(20, 21).
So far, limited information exists on the interrelation-
ship between different ectopic fat depots and cardiac fat
stores in the MetS subjects free of clinical cardiovascular
disease. Therefore, the present study focused on different
components of cardiac steatosis and their relationship to
intra-abdominal ectopic fat deposits, including liver fat,
and also on their association with a broad panel of car-
diometabolic risk factors in nondiabetic men with and
without the MetS.
Materials and Methods
Study population
A total of 77 men were recruited for the study by advertise-
ments in local newspapers. Subjects were allocated into 2 groups
(cardiometabolic risk factors present or absent, ie, with or with-
out the MetS) based on the following criteria: 1) waist circum-
ference (WC) 94 cm, and 2) having 2 abnormal findings as
per the harmonized definition of the MetS (19). Exclusion cri-
teria included no known acute or chronic disease based on his-
tory, physical examination, and standard laboratory tests (blood
counts, creatinine, aspartate aminotransferase [AST], alanine
aminotransferase [ALT], thyroid-stimulating hormone), type 2
diabetes mellitus (based on a 2-h oral glucose tolerance test),
significant alcohol consumption defined as more than 20 g per
day, and treatment with lipid-lowering therapy except for st-
atins. Only men were included because the hormonal status or
use of contraceptives modify lipid metabolism in women. Ele-
vated liver enzymes were allowed. Five subjects were receiving
medications for hypertension; 3 subjects were receiving medica-
tions for dyslipidemia (statins), and 1 subject was receivingmed-
ications for both hypertension and dyslipidemia.
Thirty-seven participants fulfilled the criteria for theMetS. In
these participants myocardial ischemia was excluded by means
of adenosine stress magnetic resonance (MR) perfusion. The
Helsinki University Central Hospital Ethics Committee ap-
proved the study design, and each subject provided written in-
formed consent.
Demographic variables and biochemical
investigations
Body mass index (BMI) was calculated by dividing weight in
kilograms by height in meters squared (kg/m2). WC was deter-
mined midway between spina iliaca superior and the lower rib
margin. BloodpressurewasmeasuredbyBPM-200 (QuickMed-
ical, Snoqualmie, Washington) in the sitting position after a
5-minute rest and the mean of 5 measurements was recorded.
The subjects were classified as present, past, or nonsmokers.
Blood samples were collected after overnight fasting. Total
serum cholesterol, TG, very low-density lipoprotein cholesterol
(VLDL-1) TG,HDL-C, free fatty acids, apolipoproteinA-I, apo-
lipoproteinB, andhigh-sensitivityC-reactiveprotein (CRP)were
automatically analyzed byKonelab analyzer 60i (Thermo Fisher
Scientific Oy, Vantaa, Finland) with Konelab TM kits. The con-
centration of low-density lipoprotein cholesterol was calculated
using the Friedewald formula (22). Measurement of AST, ALT,
creatinine, and thyroid-stimulating hormone was performed us-
ing standard laboratory techniques. Fasting and postload glu-
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cose were determined by the hexokinase method (Roche Diag-
nostic Gluco-quant, Mannheim, Germany) using either a
Hitachi 917 or aModular analyzer (Hitachi Ltd, Tokyo, Japan).
Serum insulin concentration was assessed by double-antibody
radioimmunoassay (Pharmacia RIA kit; Pharmacia, Uppsala,
Sweden). The insulin-resistance homeostasis model assessment
(HOMA) index was calculated using the following formula:
(fasting plasma glucose  fasting plasma insulin)/22.5 (23).
Determination of myocardial and hepatic
triglyceride content
Myocardial and hepatic TG content and fat depot volumes
weremeasured and cardiac imagingwas performedwith a 1.5-T
(MAGNETOM Avanto; Siemens AG, Erlangen, Germany)
whole-bodyMR imager. Formeasuringmyocardial TG content,
the spectroscopic volume of interest was positioned within the
interventricular septum using the end-systolic cardiac cine im-
ages in 3 planes. A carefully positioned standard flex-coil was
used for signal reception. The localizer images and spectroscopic
data acquisition were double-triggered to end-exhalation and
end-systole, using Prospective Acquisition Correction navigator
echoes (PACE, WIP-sequence, program version B17, Medical
Solutions USA Inc, New York, New York) to control for respi-
ratory movement and electrocardiograph-derived R wave to
control for cardiac pulsation. Spectral localization and data col-
lection were performed with the PRESS sequence with 35-ms
echo time,while repetition time (TR) (TR3000ms) didnot fall
below the respiratory cycle length. Navigator echoes were col-
lected from the lung-diaphragm interface and the end-systole
triggering was set at about 80% of the resting heart rate of the
subject. Spectra were collected with and without water sup-
pression, using 32 and 4 acquisitions, respectively. Spectra
were analyzed with jMRUI v3.0 software (www.mrui.uab.es/
mrui/) (24) using theAMARESalgorithm(25) todeterminewater
(4.7 ppm), methylene (1.3 ppm), and methyl (0.9 ppm) resonance
areas. Themyocardial TGcontentwas expressed as a ratio of fat to
water (%). Relaxationwas not corrected for as no reliable data are
available for cardiac methylene T2 relaxation.
The measurement of hepatic TG content was performed as
previously described (26). The hepatic MRS data were collected
using a standard body coil and liver spectra were analyzed with
jMRUI v3.0 software (24) using theAMARES algorithm (25), as
was done for the myocardial spectra. Areas of water signal (4.7
ppm) and methylene (1.3 ppm) were determined using a line-
fitting procedure. Hepatic TG content was calculated as meth-
ylene/(watermethylene) signal area 100 and the valueswere
further converted tomass fractions (27).Nonalcoholic fatty liver
diseasewas defined as hepaticTGcontent5.56%of liver tissue
weight (28).
Determination of abdominal fat volumes
The distribution of VAT and subcutaneous adipose tissue
(SAT) was measured using a series of 16 T1-weighted transaxial
images acquired from a region extending from 8 cm above to 8
cm below the fourth and fifth lumbar intervertebral disks (26),
using a standard body coil for image acquisition. MR images
were analyzed using SliceOmatic v4.3 (Tomovision, Montreal,
Quebec, Canada) segmentation software. The areas of SAT and
VAT were measured for each slice using a region-growing rou-
tine. The results were expressed as total volumes of SAT and
VAT. We also calculated the VAT/SAT ratio as a metric of ab-
dominal fat distribution (29).
Cardiac MR imaging and LV analysis
For cardiac imaging a multichannel body coil was used for
reception. Cine series were acquired in 4-chamber, 2-chamber,
and LV short-axis orientations during breath-hold using a ret-
rospectively electrocardiographically gated steady-state free pre-
cession gradient echo sequence. A stack of short-axis cine series
(typically 12 slices) was acquired from base to apex covering the
whole LV. Typical imaging parameters were TR/echo time/flip
angle 50ms/1.18ms/69°,matrix 186220, field-of-view355
420 mm, slice thickness 8 mm, gap 2 mm, and temporal reso-
lution 32–53 ms.
Volumetric analysis of theLVwas scrutinizedusingdedicated
postprocessing software (Argus; Siemens). LV ejection fraction
(EF), mass, and end-diastolic volume were reported, and mass
and end-diastolic volume were indexed to the subject’s body
surface area (BSA). LV mass was also indexed to height2.7 (30).
Determination of epicardial and pericardial fat
Segmenting the epicardial and pericardial fat planes is very
time consuming and standardized measurement is challenging
due to anatomical variety. In our preliminary data, epicardial
and pericardial fat areas measured in a single 4-chamber-view
slice showed good correlationwith epicardial and pericardial fat
volumes measured with conventional Simpsonmethod covering
both right and left ventricles in a stack of short-axis image slices
(n  6, r  0.895, P  .02). Therefore we used epicardial and
pericardial adipose tissue areas measured in a 4-chamber-ori-
ented image to estimate the amount of epicardial and pericardial
fat, a method also used by others (31).
Epicardial fat is by definition the layer of adipose tissue be-
tween the myocardium and the visceral sheet of pericardium.
This epicardial fat shows inMRas ahigh-intensity layer between
the lower intensitymyocardium and the low-signal-intensity vis-
ceral pericardium. In determining the area of the epicardial fat
layer, all phases of the cine images were inspected and measure-
Figure 1. Contours of the epicardial (shown in green) and pericardial
(shown in blue) fat in end-diastolic 4-chamber-oriented image.
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ment was performed in the end-diastolic image using standard
radiologic workstation (Impax 5.5 software; Agfa Healthcare,
Mortsel, Belgium). Pericardial fat, which is a continuum of the
thoracic or mediastinal adipose tissue outside the parietal peri-
cardium, was measured in the same end-diastolic 4-chamber-
oriented image as epicardial fat (Figure 1).
Statistical analyses
All statistical analyses were performed with SPSS 19.0 for
Windows (SPSS, Inc,Chicago, Illinois).Normality of continuous
variables was analyzed by the Kolmogorov-Smirnov test. Log-
arithmic transformation of variables was performed, if neces-
sary. Correlation analyses were adjusted for both age and smok-
ing status. Data are presented as frequencies or percentages for
categorical variables, as means  SD for normally distributed
continuous variables, and as medians (range) for skewed vari-
ables. Between-group differences were assessed by the Mann-
Whitney U test, unpaired t test, and the 2 test, as appropriate.
Todetect determinants ofmyocardial TGcontent, epicardial fat,
pericardial fat, hepatic TG content, visceral fat, and VAT/SAT
ratio univariate regression analyses were performed. Stepwise
multivariable linear regressionanalyseswereused to evaluate the
impact of fat depots on individual cardiometabolic factors as
dependent variables. To adjust for confounding, age was in-
cluded in all models. A P value.05 was considered statistically
significant.
Results
The clinical and biochemical characteristics of the study
population are summarized in Table 1. Subjects with the
MetSwere older than thosewithout theMetS. In theMetS
group, 24 subjects had normal glucose tolerance, 4 had
impaired fasting glucose, and 9 had impaired glucose tol-
erance. All individuals in the non-MetS group had normal
glucose tolerance. Thereweremore current smokers in the
MetS group than the group without the MetS. Total cho-
lesterol, low-density lipoprotein cholesterol, apolipopro-
tein B, high-sensitivity CRP, free fatty acids, AST, ALT,
fastingglucose, fasting insulin, and theHOMAindexwere
higher in individuals with the MetS compared with those
without the MetS. The lipid profile showed robust differ-
ences between the 2 study groups. Most subjects with the
MetS had elevated TGs (n  24; 65%) representing par-
Table 1. Clinical and Biochemical Characteristics of the Study Groups
MetS Present MetS Absent P
n (males) 37 40
Age, y 47  6 40  8 .001
BMI, kg/m2 30.9 (24.2–42.5) 23.4 (17.6–29.8) .001
WC, cm 107.0 (94.0–135.0) 87.0 (71.0–93.5) .001
Systolic BP, mm Hg 132  14 115  10 .001
Diastolic BP, mm Hg 88  9 74  6 .001
Current smokers, n (%) 13 (35) 5 (12) .019
Total cholesterol, mmol/L 5.25  0.74 4.41  0.79 .001
Low-density lipoprotein cholesterol, mmol/L 3.25  0.71 2.54  0.66 .001
HDL-C, mmol/L 1.02  0.26 1.50  0.39 .001
TGs, mmol/L 2.20 (0.65–6.26) 0.78 (0.35–1.57) .001
VLDL1-TGs, mmol/L 1.52 (0.29–4.65) 0.47 (0.07–1.29) .001
Apolipoprotein A-I, mg/dL 132  18 142  20 .033
Apolipoprotein B, mg/dL 117  25 74  17 .001
High-sensitivity CRP, mg/L 1.8 (0.2–11.8) 0.2 (0.0–5.8) .001
Fasting free fatty acids, mol/L 524  172 450  198 .089
fP-ALT, U/L 39 (20–259) 21 (7–59) .001
fP-AST, U/L 30 (23–119) 29 (19–53) .076
fP-glucose, mmol/L 5.8 (4.6–6.9) 5.0 (4.4–6.0) .001
fS-insulin, mU/L 9.3 (3.3–36.9) 2.9 (0.9–7.7) .001
HOMA index 2.6 (0.8–8.0) 0.6 (0.2–2.0) .001
Myocardial TG content, % 0.90 (0.31–2.33) 0.44 (0.14–1.39) .001
Epicardial fat, mm2 838 (385–1753) 520 (251–1129) .001
Pericardial fat, mm2 1905 (615–6131) 562 (66–1582) .001
Hepatic triglyceride content, % 6.59 (0.40–31.74) 0.73 (0.17–4.45) .001
Visceral fat, cm3 3304 (1257–5743) 843 (67–3170) .001
Subcutaneous fat, cm3 4816 (2216–9354) 1773 (284–4017) .001
VAT/SAT ratio 0.63 (0.26–1.64) 0.46 (0.13–1.23) .001
LV EF, % 61  6 62  4 .641
LV end-diastolic volume/BSA, mL/m2 65  13 84  11 .001
LV mass, g 128  22 123  15 .207
LV mass/BSA, g/m2 58  9 62  7 .033
LV mass/height2.7 26  5 24  5 .083
Abbreviations: fS, fasting serum; fP, fasting plasma. Data are expressed as means (SD), medians (range), or frequencies (%).
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ticipants with hypertriglyceridemic waist. Notably, both
TGs and VLDL-1 TGs were about 3-fold higher in the
groupwith theMetS comparedwith the groupwithout the
MetS. As expected, BMI and WC were higher in subjects
with the MetS than in those without the MetS.
Visceral and subcutaneous fat masses were markedly
higher in the group with theMetS being increased by 3.9-
fold and 2.7-fold compared to the group without the
MetS. In participants with the MetS the hepatic TG con-
tent was10-fold higher than in those without theMetS.
Myocardial TG content was increased by 2-fold (P 
.001). Similarly, the epicardial and pericardial fat were
clearly higher in subjects with the MetS compared with
subjectswithout theMetS.All study subjects had anormal
LV EF. LV end-diastolic volume indexed to BSA was de-
creased in theMetS group compared with the groupwith-
out the MetS (Table 1).
Visceral fat correlated significantly with hepatic TG
content as well as with WC and BMI. Although a signif-
icant correlation existed between hepatic TG content and
VAT/SAT ratio, this was less strong thanwith visceral fat.
Further analyses revealed that all components of cardiac
steatosis correlated with subcutaneous and visceral fat
masses, and hepatic TG content and the correlations
seemed to be stronger with visceral fat than with subcu-
taneous fat or hepatic TG content (Table 2 and Figure 2).
The VAT/SAT ratio correlated with hepatic TG content,
epicardial fat, and pericardial fat, but not as strongly as
with visceral fat. The VAT/SAT ratio was not correlated
with myocardial TG content (Table 2).
Table 2. Univariate Correlation Analyses Between Myocardial Triglyceride Content, Epicardial Fat, Pericardial Fat,
Hepatic TG Content, Visceral fat, VAT/SAT Ratio, and Different Study Parameters Adjusted for Age and Smoking
Status
Myocardial TG
Content
Epicardial
Fat
Pericardial
Fat
Hepatic TG
Content
Visceral
Fat
VAT/SAT
Ratio
Demographic variables
Age 0.369b 0.221 0.323b 0.221 0.416c 0.510c
WC 0.426c 0.571c 0.464c 0.607c 0.842c 0.129
BMI 0.405c 0.587c 0.445c 0.584c 0.807c 0.063
Systolic BP 0.089 0.395b 0.358b 0.308b 0.401c 0.087
Diastolic BP 0.170 0.419c 0.395c 0.413c 0.493c 0.118
Lipid profile
Total cholesterol 0.159 0.128 0.231a 0.037 0.146 0.091
HDL-C 0.292a 0.322b 0.382b 0.321b 0.590c 0.286a
LDL cholesterol 0.136 0.075 0.214 0.051 0.211 0.162
TGs 0.315b 0.374b 0.424c 0.254a 0.486c 0.183
VLDL-1 TG 0.356b 0.406c 0.443c 0.229a 0.442c 0.165
Apolipoprotein A-I 0.185 0.079 0.154 0.161 0.336b 0.152
Apolipoprotein B 0.312b 0.299a 0.392b 0.221 0.488c 0.189
Glucose tolerance and fatty acids
Fasting plasma glucose 0.537c 0.195 0.304b 0.369b 0.445c 0.143
Fasting plasma insulin 0.373b 0.564c 0.484c 0.508c 0.648c 0.213
HOMA-IR 0.463c 0.562c 0.494c 0.536c 0.761c 0.228a
Free fatty acids 0.020 0.028 0.074 0.011 0.017 0.128
Inflammation biomarker
High-sensitivity CRP 0.082 0.261a 0.128 0.229 0.373b 0.110
Liver enzymes
ALT 0.064 0.437c 0.358b 0.402c 0.386b 0.059
AST 0.057 0.307b 0.281a 0.222 0.241a 0.053
Fat depots
Myocardial TG content — 0.198 0.141 0.353b 0.463c 0.219
Epicardial fat 0.198 — 0.673c 0.581c 0.645c 0.269a
Pericardial fat 0.141 0.673c — 0.552c 0.655c 0.497c
Hepatic TG content 0.353b 0.581c 0.552c — 0.779c 0.477c
Visceral fat 0.463c 0.645c 0.655c 0.779c — 0.537c
Subcutaneous fat 0.343b 0.550c 0.380b 0.514c 0.764c 0.028
VAT/SAT ratio 0.216 0.269a 0.497c 0.476c 0.537c —
LV function
LV EF, % 0.044 0.094 0.057 0.225 0.098 0.221
LV end-diastolic volume/BSA, mL/m2 0.329b 0.433c 0.454c 0.411c 0.639c 0.332b
LV mass (g) 0.106 0.001 0.128 0.022 0.082 0.280a
LV mass/BSA, g/m2 0.098 0.291a 0.345b 0.246a 0.317b 0.355b
LV mass/height2.7 0.092 0.049 0.069 0.087 0.116 0.294a
a P  .05; b P  .01; c P  .001. — indicates the variable cannot be correlated with itself.
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Myocardial TG content, epicardial fat, pericardial fat,
hepatic TG content, and visceral fat showed significant
correlations with WC, BMI, HDL-C, TGs, VLDL-S TGs,
plasma insulin, and the HOMA index. High-sensitivity
CRP was linked to epicardial and visceral fat. The VAT/
SAT ratio showedmoderate correlationswithHDL-Cand
the HOMA index. LV end-diastolic volume as well as LV
end-diastolic volume indexed to BSA correlated with epi-
cardial fat, pericardial fat, hepaticTGcontent, visceral fat,
and theVAT/SAT ratio.Onlymyocardial TG contentwas
associated with LV end-diastolic volume indexed to BSA
(Table 2).
Next we used stepwise multivariable regression analy-
ses to evaluate the impact of fat depots on individual car-
diometabolic risk factors. Visceral fat was an independent
predictor ofTGs,HDL-C, plasmaglucose, plasma insulin,
and the HOMA index, whereas age and subcutaneous fat
were independent determinants of systolic and diastolic
blood pressure (BP) (Table 3).
Discussion
To the best of our knowledge, this is the first study to use
MR technology to examine cardiac steatosis by quantify-
ing simultaneously all 3 cardiac fat stores as well as to
relate these data to intra-abdominal fat depots, including
liver fat also in a large nondiabetic group of abdominally
obese men free of clinical cardiovascular disease.
The definition of MetS was used as a tool to identify
obese subjects at high cardiometabolic risk in this study.
We consistently found an2-fold elevation inmyocardial
and epicardial fat, respectively, and an3-fold elevation
in pericardial fat depot in subjectswith theMetS. The data
show thatmyocardial TG content correlatedwith visceral
fat, hepatic TG content, and multiple parameters of over-
all obesity. In multivariable regression analyses, visceral
fat remained an independent predictor of TGs, HDL-C,
plasma glucose, plasma insulin, and the HOMA index,
whereas age and subcutaneous fat were independent de-
Figure 2. A–I, Correlations between different ectopic fat depots. The values in figures are adjusted to age and smoking status. The open circles
indicate subjects in the MetS group and the filled circles indicate subjects in the group without the MetS.
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terminants of systolic and diastolic BP. The association of
multiple cardiometabolic risk factorswithmyocardial TG
content, pericardial fat, and epicardial fat agreeswith pre-
vious studies (32, 33).
So far,most studies havemeasured either pericardial or
epicardial fat depots because their quantification is tech-
nically easier than that of lipids in cardiomyocytes, the
latter requesting a more sophisticated technique. Overall,
both pericardial and epicardial fat depots associate with
the amount of visceral fat that is increased in obesity, sub-
jects with MetS, impaired glucose tolerance, and subjects
with type 2 diabetes mellitus (32). It should be recognized
that the 3 cardiac sites differ in their capacity to accumu-
late fat with the pericardial site having the greatest capac-
ity and cardiomyocytes having the lowest capacity. Thus,
increase of cardiac fat depots in men with the MetS in
context of visceral adiposity is not a surprising finding. In
our cohort, the VAT/SAT ratio as a measure of organ-
specific fat distribution did not provide any clear benefits
beyond visceral fat mass.
Our data confirm and expand the results by Gaborit et
al (34), who reported that epicardial fat volume andmyo-
cardial TG content were increased in individuals with the
MetS. Notably, the 2 studies show differences in partici-
pants because the cohort of Gaborit et al (34) exhibited
extreme obesity (BMI range, 33 to 52 kg/m2), including
only 18 subjects with the MetS, and reported no data on
hepatic TG content. Our results expand previous obser-
vations of increased myocardial lipid accumulation in in-
sulin-resistant states in subjects with impaired glucose tol-
erance and type 2 diabetes mellitus to abdominally obese
men with cardiometabolic risk factors (10–12). All 3 car-
diac fat depots showed broadly similar significant corre-
lations with measures of apolipoprotein B containing
lipoproteins, HDL-C, and parameters of glucose homeo-
stasis. Visceral fat was an independent predictor of TGs,
HDL-C, and measures of glucose metabolism, but subcu-
taneous fat was the determinant of BP parameters. The
data highlight that visceral adiposity lies at the root of the
systemic effects linked to ectopic fat depots quantified by
MR technology, as proposed also by Despre´s (18).
Table 3. Results of Stepwise Multivariable Regression
Analyses
Independent Variables  P
Dependent variable: TGs (log)
Age .107 .252
Myocardial triglyceride content (log) .088 .419
Epicardial fat (log) .083 .479
Pericardial fat (log) .213 .091
Hepatic TG content (log) .203 .215
Visceral fat (log) .654 <.001
Subcutaneous fat (log) .265 .097
Adjusted R2 .488 <.001
Dependent variable: HDL-cholesterol
Age .242 .021
Myocardial TG content (log) .123 .311
Epicardial fat (log) .029 .821
Pericardial fat (log) .155 .272
Hepatic triglyceride content (log) .268 .141
Visceral fat (log) .686 <.001
Subcutaneous fat (log) .098 .584
Adjusted R2 .364 <.001
Dependent variable: fasting plasma glucose
(log)
Age .030 .777
Myocardial TG content (log) .243 .050
Epicardial fat (log) .070 .595
Pericardial fat (log) .037 .797
Hepatic triglyceride content (log) .170 .373
Visceral fat (log) .411 .002
Subcutaneous fat (log) .215 .238
Adjusted R2 .345 <.001
Dependent variable: fasting plasma insulin (log)
Age .009 .892
Myocardial TG content (log) .040 .598
Epicardial fat (log) .087 .282
Pericardial fat (log) .033 .708
Hepatic triglyceride content (log) .078 .496
Visceral fat (log) .618 <.001
Subcutaneous fat (log) .291 .011
Adjusted R2 .752 <.001
Dependent variable: HOMA index (log)
Age .004 .946
Myocardial TG content (log) .012 .875
Epicardial fat (log) .073 .351
Pericardial fat (log) .022 .795
Hepatic triglyceride content (log) .100 .362
Visceral fat (log) .613 <.001
Subcutaneous fat (log) .301 .006
Adjusted R2 .769 <.001
Dependent variable: systolic BP
Age .328 .001
Myocardial TG content (log) .030 .797
Epicardial fat (log) .126 .289
Pericardial fat (log) .149 .222
Hepatic triglyceride content (log) .177 .220
Visceral fat (log) .159 .420
Subcutaneous fat (log) .452 <.001
Adjusted R2 .358 <.001
(Continued)
Table 3. Continued
Independent Variables  P
Dependent variable: diastolic BP
Age .238 .013
Myocardial TG content (log) .047 .688
Epicardial fat (log) .120 .304
Pericardial fat (log) .145 .227
Hepatic triglyceride content (log) .187 .189
Visceral fat (log) .207 .284
Subcutaneous fat (log) .534 .001
Adjusted R2 .379 .001
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The inefficient storage capacity of SATmass in the face of
extracaloric intake results inexcessive flowof free fattyacids
into systemic circulation, driving the overload of free fatty
acids into ectopic fat depots (18). In this concept, expansion
of visceral, pericardial, and epicardial fat depots represents
visceral components and the preferential places to store ex-
cess dietary fats. Our data support the concept that visceral
fat depot is indeed the priority site for excess fat storage.
Moreover, pericardial and epicardial fat depots are interre-
lated with visceral fat and good markers of ectopic fat de-
position. The constellation of these 3 fat depots is linked to
the development of the cardiometabolic risk profile, includ-
ing disturbances of both glucose and lipid metabolism. In
addition, products (like cytokines) of epicardial fat can have
local effects on myocardial metabolism.
The liver plays a central role in controlling lipid and free
fatty acid metabolism. Notably, the liver is exposed to
first-pass free fatty acids from visceral fat depot. Recog-
nizing the strong correlation between visceral fat and he-
patic TG content, it was not surprising that hepatic TG
content showed a correlation with myocardial TG con-
tent. Likewise, McGavock et al (12) reported a modest
correlation between hepatic and myocardial TG content.
However, we did not find any correlation between myo-
cardial TG content and epicardial or pericardial fat de-
pots. This finding suggests that fat accumulation in car-
diomyocytes may also be regulated by other factors than
those linked to systemic fat depositions.
The study design does not allow us to evaluate the mo-
lecularmechanisms underlying cardiac steatosis. It should
be recognized that lipid accumulation in cardiomyocytes
reflects the imbalance between uptake and utilization of
free fatty acids. Excessive uptake of free fatty acids by
cardiomyocytes associates with accelerated fatty acid ox-
idation instead of glucose oxidation and may elicit lipo-
toxicity reflected as impaired cardiac function (17, 35).
Another source for increased lipid uptake by cardiomyo-
cytes is the uptake of lipids from TG-rich lipoproteins
mediated by VLDL receptor and lipoprotein lipase cata-
lyzedhydrolysis ofTGs (36,37).Recentdata suggest a link
between VLDL receptor expression and lipid droplets in
human cardiomyocytes (37). Interestingly, both concen-
trations of TG in serum and large VLDL-1 particles cor-
related with each cardiac fat depot and liver fat. We have
previously reported that hepatic TG represents the driving
force for VLDL assembly and secretion of large VLDL-1
particles (38). This may explain in part the correlation
between hepatic and myocardial TG content. If the oxi-
dative capacity of mitochondria is exceeded, cardiac ste-
atosis is ensued, compromising cardiac function. The ob-
jective of this report was not to examine the parameters of
cardiac function in-depth; however, LV end-diastolic vol-
ume index was decreased despite comparable LV EF, sug-
gesting diastolic dysfunction in subjects with the MetS.
This is in agreement with previous reports (10, 13, 34).
Study limitations
A limitation of the methodology in the study is the nar-
row range of myocardial TG content measured by 1H
MRS in healthy subjects, which has been reported to be
less than or about 1% (8, 39). In linewith this,myocardial
TG content was low in most lean subjects and this may
underestimate its association with metabolic parameters
as compared to pericardial fat. Both gender and age may
influence the magnitude of cardiac steatosis, although the
data are not consistent (33, 34). Accordingly, only men
were included in this study and the data were adjusted to
age. However, recent reports have documented the in-
crease ofmyocardial TG content in insulin-resistant obese
women also (40). Finally, this study has a cross-sectional
design that limits our ability to infer any causality.
Conclusions
Our study is the first to investigate cardiac lipotoxicity in
a large nondiabetic group of abdominally obese men. We
conclude that visceral obesity is the best predictor of epi-
cardial and pericardial fat in abdominally obese subjects.
We suggest that all 3 depots comprise a common constel-
lation in face of extra free fatty acid flux. Myocardial TG
content may present a separate entity that is also influ-
enced by other factors than the excess visceral obesity.
Furthermore, longitudinal studies with a specific focus on
parameters of cardiac function are needed to elucidate
potential differences in organ-specific lipid accumulation
in the setting of excess caloric intake.
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